INTRODUCTION
The main barrier to HIV eradication is the ability of HIV-1 to establish latency in long-lived resting CD4 + T cells (1, 2) , which persist in blood and tissues (3) (4) (5) (6) . Quiescent CD4 + T cells harboring latent HIV do not produce virus until they are activated to produce infectious virus (7) (8) (9) (10) (11) (12) (13) (14) . These latently infected cells are likely the source of rebound after interruption of antiretroviral therapy (ART), and their continual reactivation in vivo probably contributes to ongoing immune activation, inflammation, and organ damage that persists even under suppressive ART (15) (16) (17) (18) (19) (20) (21) (22) (23) .
Despite nearly two decades of research, it remains unclear what mechanisms govern latency in vivo and persistence of HIV after therapy. One major obstacle to progress is the inability to distinguish and identify latently infected cells in vivo, which has precluded a full understanding of HIV latency and hampered the development of curative strategies. Because latently infected cells express little or no HIV RNA or protein, strategies for eliminating HIV latency will likely require identification of host factors that can be used to identify and target latently infected cells.
Recently, Descours et al. (24) suggested that CD32a (FcRIIa), an Fc receptor mainly expressed on myeloid cells and platelets, is a potential biomarker of the CD4 + T cell HIV reservoir harboring replication-competent proviruses in ART-suppressed individuals. However, because this report did not exclusively define resting versus activated CD4 + T cells, it remains unclear whether CD32a is specifically enriched in resting latently infected CD4 + T cells. Previous studies have demonstrated that CD32 is rarely expressed by resting CD4 + T cells (25, 26) compared to activated T cells (27) (28) (29) , further stressing the need to characterize CD32 expression on resting CD4 + T cells in HIV-infected individuals. To address this issue, we examined whether CD32 is associated with resting or activated CD4 + T cells in ART-treated individuals, whether CD32 expression can enrich for HIV DNA copies in total or resting CD4 + T cells, and whether it aligns with latent or transcriptionally active HIV-infected CD4 + T cells.
RESULTS

CD32 + CD4 + T cells are enriched with activated cells rather than with resting cells HIV latency has been functionally defined in resting CD4
+ lymphocytes (CD4 + , CD69 − , CD25 − , and HLA-DR − ), which lack expression of virions or viral antigens (7, (30) (31) (32) (33) (34) (35) . We measured CD4
+ T cell surface expression of CD32 and activation markers [CD69 for early activation, CD25 for intermediate or late activation, and human leukocyte antigen-DR (HLA-DR) for late activation] using flow cytometry on fresh blood from ART-suppressed HIV-infected individuals with <50 copies/ml of plasma viral load (VL), HIV-infected individuals with VL >50 copies/ml, and HIV − controls (table S1) . We also assessed the expression of CD32 on cryopreserved peripheral blood mononuclear cells (PBMCs) from ART-suppressed HIV-infected individuals. CD32 was detected on the surface of CD4 + T cells from (i) HIV − controls [median, 5.7%; interquartile range (IQR), 4 .1%], (ii) HIV + individuals with VL <50 copies/ml (median, 4%; IQR, 1.95%), and (iii) HIV + individuals with VL >50 copies/ml (median, 3.1%; IQR, 3%) (Fig. 1A) . The frequency of CD32 on fresh CD4 + T cells in ART-suppressed HIV + individuals (median, 4%; IQR, 1.95%) was significantly higher (P < 0.0001) than that on frozen cells (median, 0.41%; IQR, 0.3%) (Fig. 1B) . Despite the frequency difference, there was no phenotypic difference between CD32 + CD4 + T cells from fresh and frozen samples. Following the gating strategy used by Descours et performed using two-tailed Wilcoxon rank tests. n = 6 for HIV − controls, n = 27 for HIV + ART + (<50 copies/ml) individuals, and n = 7 for HIV + (>50 copies/ml) individuals.
*P < 0.05 and ****P < 0.0001.
with VL <50 copies/ml, and P = 0.016 in HIV + individuals with VL >50 copies/ml). We further found that most memory CD32 + CD4 + T cells expressed one or more activation markers (Fig. 2, C and D) , independent of HLA-DR alone. Whereas HLA-DR + cells generally expressed other activation markers, CD32 + HLA-DR − cells showed similarly high activation profiles, including significantly higher frequencies of CD38 + (P < 0.0001) and Ki67 + (P < 0.0001) cells, compared to CD32 − cells. We also observed that memory CD32 + CD4 + T cells had lower frequencies of programmed cell death protein 1 (PD-1) and CD57 when compared with memory CD32 − cells (P = 0.017 and P < 0.0001, respectively). Of note, CD32 + naïve CD4 + T cells also had higher frequencies of activation markers compared to CD32 − cells (P = 0.035 for HLA-DR, P = 0.0005 for CD38, and P < 0.0001 for Ki67).
Finally, we incorporated the analyzed parameters within memory CD32 + and CD32 − CD4 + T cells and performed unbiased clustering and principal components analyses (PCAs) of the entire data set (Fig. 2, E + T cells, subset distribution, and phenotype in tonsil samples from ART-treated HIV-infected individuals from the Philadelphia cohort ( Fig. 3 and fig. S4 fig. S4 , A to C). We first analyzed the distribution of CD32 + HLA-DR − CD4 + T cells in memory subsets in tonsils, and similar to our observation in blood (Fig. 2) , T CM was the most frequent memory subset (median, 52.8%; IQR, 24.9%; Fig. 3A) . In contrast to our findings in blood (Fig. 2) fig. S5 ). Overall, these data dem onstrate that the frequency and phenotype of CD32 + cells in lymphoid tissues analyzed largely parallel those in the peripheral blood.
CD32 expression associates with productive HIV infection in vitro and ex vivo
To investigate the direct effect of HIV replication on CD32 expression, ex vivo infection kinetics were examined using unstimulated PBMCs from three healthy donors. Cells were infected for up to 6 days and subjected to the RNA fluorescence in situ hybridization ( *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. (Fig. 4C ). Of note, uninfected cells expressed very low frequencies of both HLA-DR and PD-1 (1.8 and 1.1%, respectively). Given that CD32 expression has been shown to increase after in vitro polyclonal activation (36), we then focused on HIV infection of previously activated CD4 + T cells. We observed an increase of CD32 in uninfected CD4 + T cells after 72-hour exposure to anti-CD3/CD28 antibodies compared to controls (P = 0.007; n = 8). As with nonactivated cells, we also found that HIV NL4-3 infection of activated cells further up-regulates the frequency of CD32 + cells (Fig. 4D) (Fig. 4F) . Overall, after ex vivo infection of unstimulated PBMCs and cervical tissue, ~15% of infected cells expressed the CD32 marker, and this pop ulation had higher HLA-DR and PD-1 frequencies than their CD32 − counterparts. formed on CD32 pull-downs with anti-CD32 antibody-conjugated magnetic beads (with PBMCs from HIV + ART-suppressed individuals) and compared to preimmunoprecipitation pull-downs normalized for cell numbers. We did not detect any enrichment of HIV DNA in CD4 + CD32 + pull-downs relative to controls (Fig. 5A ). In addition, we used anti-CD32 antibody-conjugated magnetic beads (Fig. 5B) . Finally, we measured HIV DNA in CD4 + T cells FACS (fluorescenceactivated cell sorting)-sorted based on activation status and CD32 expression as shown in Fig. 5C . All sorted populations were isolated within 2 hours of collection of blood from HIV + ARTsuppressed individuals (Fig. 5C Fig. 6 (A and B) and fig. S6 (A  to D)] ; however, the frequency of CD32 + CD69 + CD4 + T cells exhibited a moderate significant correlation with total HIV DNA load in isolated CD4 + T cells from HIV + ART-suppressed individuals (rho = 0.44, P = 0.036) (Fig. 6, C and D 
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CD32 expression associates with HIV-RNA in LNs of HIV-infected patients
To better understand the relationship between HIV RNA and CD32a expression, we visualized and quantified HIV RNA and CD32a RNA in anatomically intact LN tissue from viremic and ART-treated HIV-infected patients, and HIV − controls. HIV RNA and CD32a RNA were detected in paraffin-embedded tissue samples. As shown in Fig. 7A , we observed two HIV RNA expression patterns: (i) productively HIV-infected cells that typically have a densely staining spherical signal that involves the entire cell and (ii) small punctate structures with a diffuse lattice-like signal pattern compatible with the capture of HIV virions by follicular dendritic cells in B cell follicles, as reported previously (37) . Of note, we did not perform the phenotypic identification of transcriptionally active infected cells in LNs, but reports have shown that productively HIV-infected cells align with CD45RO + memory CD4 + T cells (38) . Using a specific set of RNA probes, we evaluated CD32a expression. The observed staining and localization of CD32a were compatible with the presence of subcapsular sinus macrophages in LNs. In addition, in the analyzed six HIV-infected patients, a high percentage of HIV-expressing cells localized within the B cell follicle also coexpressed the CD32a transcripts (median, 94%) compared to 4% of cells that were single CD32a + and 2% of cells that only expressed HIV RNA. The B cell follicle has been identified as an immune-privileged sanctuary site for HIV persistence (39) . No differences were observed between viremic and aviremic donors (Fig. 7B) . After inspecting a median of 74 B cell follicles per donor, CD32a single-positive cells were detected at a median frequency of 6.3% in viremic and 1.7% in ART-treated patients. Cells coexpressing the CD32a receptor and HIV RNA were detected at a median frequency of 94.3% in viremic and 60.2% in ART-treated patients (Fig. 7C and fig. S8 ). Of note, CD32a was highly up-regulated in HIV RNA-positive HIV-infected cells. The expression for both RNAs, HIV and CD32a [defined by the mean fluorescence intensity (MFI)], was highly correlated in all analyzed patients (Fig. 7D) . Overall, in LNs of HIV-infected patients, most of the cells expressing HIV RNA also coexpress the CD32a receptor, whereas CD32a single-positive cells within the B cell follicle were rarely observed.
DISCUSSION
We report that CD32 expression in CD4 + T cells is a marker for a subset of activated CD4 + T cells containing HIV transcripts after ART-mediated suppression. We find no evidence to support that CD32 expression favors resting CD4 + T cells or enriches for HIV DNA copy number in sorted resting CD4 + T cells commonly used to measure the latent HIV reservoir. We found evidence that CD32 expression favors activated CD4 + T cells and is coexpressed with HIV RNA in infected cells in vitro and in vivo.
Our T cells contribute the most to the total pool of HIV DNA in total CD4 + T cells (~76%), whereas CD32 + CD4 + T cells, activated or resting, contribute minimally to this pool (4.7 and 2.2%, respectively). These results challenge the notion that CD32 enriches for HIV latently infected cells as suggested by Descours et al. (24) . The reasons for this discrepancy remain unclear.
Although the expression of low-affinity Fc receptors, including CD32, on CD4 + T cells remains controversial (25, 26) , resting CD4 + T cells express low frequencies of CD32, whereas CD32 expression increases upon T cell activation (27) (28) (29) 40) . We found that expression of CD32 is enriched within cells expressing markers routinely used to deplete activated cells when studying HIV latency (CD69, HLA-DR, and CD25) (7, (30) (31) (32) (33) (34) (35) . Activation levels of the donor samples used in the report by Descours et al. were not reported. Therefore, it remains unclear whether the lower viral outgrowth from CD32-depleted CD4 + T cells reported by Descours et al. reflects outcomes associated with large disparities in baseline T cell activation between donors.
Immunoprofiling of CD32 + CD4 + T cells in blood and tissues of humans and RMs shows that these cells exhibit an activated and differentiated phenotype, making it unlikely that they are enriched with HIV latently infected cells. We were also unable to detect differences in the frequencies of CD32 + CD4 + T cells between HIVinfected individuals (viremic and ART-suppressed) and healthy donors, otherwise expected if CD32a was a preferential biomarker for HIV-1 infection in CD4 + T cells (irrespective of latent or active infection). It was of interest to detect enrichment of markers consistent with T H 2 cells (blood and tissue) and T H 17 cells (tissue) within CD32 + CD4 + T cells. These phenotypes have been associated with HIV persistence and enriched replication capacity in vitro and ex vivo (41) (42) (43) (44) (45) . It is important to consider, however, that the enrichment within the T H 17 observed in tonsils, but not in peripheral blood, may be due solely to the rarity of this subset in circulation compared to lymphoid tissue.
Our in vitro analyses show a direct link between CD32 + expression and productive HIV infection. Although HIV-infected CD32 Our data do not exclude the possibility that CD32 + cells are also preferentially infected. This possibility is very likely because CD32 + cells are more activated. However, these possibilities separately or jointly would not significantly affect our conclusion that a portion of cells actively transcribing HIV are also expressing CD32.
Consistent with the notion that CD32 + CD4 + T cells are enriched with transcriptionally active infection, cell-associated HIV RNA load was mostly closely associated with the activation and the expression of CD32 on CD69 + cells in both total and resting CD4 + T cells in the periphery. In addition, our RNA FISH experiments showing the coexpression of CD32a and HIV RNA in lymph tissue directly support the interpretation that CD32a is more likely to be associated with transcriptionally active rather than latent infection. The role of CD32, if any, in determining the enrichment of HIV expression remains unknown. FcRII receptors play critical roles in shaping different immunological outcomes and direct antibody functionality (46) . FcRIIa and FcRIIc are activating receptors, whereas FcRIIb is an inhibitory receptor (46) . It remains unclear which functions are mediated by the immunomodulatory CD32 receptors on CD4 + T cells with regard to HIV infection, expression, and immune evasion, especially if their expression is triggered by T cell receptormediated T cell activation.
The similarity of the extracellular domains of CD32a (FcRIIa), CD32b (FcRIIb), and CD32c (FcRIIc) does not allow us to differentiate between the three receptors by flow cytometry because there are no available antibodies that can distinguish among them, and the available CD32a-specific antibody showed very low resolution (47) . However, our RNA FISH data in LNs were generated using a CD32a-specific probe. Our data were primarily obtained from blood, LN tissues, and tonsils; thus, the need to analyze the role of CD32a expression to HIV persistence in additional tissues (such as gutassociated lymphoid tissues) after ART remains. The concordance of our data with SIV-infected macaques showing a relationship between CD32 and activation and the lack of enrichment of SIV DNA in sorted CD32 + CD4 + T cells raise the possibility that the RM model may be useful in greater tissue-centered analysis, as well as in testing strategies aimed at directly targeting CD32 + T cells. Last, our data describe cross-sectional groups in chronically infected adults, thereby the need to also analyze longitudinal changes, acute infection, and pediatric cohorts not addressed by our report.
In summary, our results show that CD32 + CD4 + T cells exhibit a distinct activation profile for transcriptionally active HIV. Although CD32 may provide a novel tool to better understand persistent HIV expression after ART, our data also stress the remaining need to find reliable and specific HIV latency biomarkers in resting CD4 + T cells for the development of effective targeting methods toward HIV eradication.
MATERIALS AND METHODS
Study design
This study was performed on fresh and frozen PBMCs, and tonsils from HIV 
Ex vivo infection kinetics of unstimulated PBMCs
PBMC samples from three healthy donors were used for these experiments. Briefly, frozen PBMCs were thawed and incubated overnight in R10 supplemented with streptomycin (100 g/ml), penicillin (100 U/ml), and interleukin-2 (IL-2; 40 U/ml). On the next day, one million PBMCs were infected with 350,000 TCID 50 (50% tissue culture infectious dose) of NL4-3 viral strain for 4 hours at 37°C and 5% CO 2 . After the initial infection, the cells were thoroughly washed and cultured in 96-well plates in R10 plus IL-2 (100 U/ml) for an additional 6 days to expand the initial viral infection. To focus our analysis on transcriptionally active HIV-infected cells, we performed the RNA FISH-flow assay at days 3, 4, 5, and 6, as previously described (48) . For HIV RNA detection, we used target-specific Alexa Fluor 647-labeled probes that contain a set of 50 probes spanning the whole Gag-Pol HIV mRNA sequence (bases 1165 to 4402; reference HXB2). We include antibodies for surface markers CD4 (BV510; BioLegend), CD3 [phycoerythrin (PE)-Cy5; BioLegend], CD32 (PE-Cy7; BioLegend), HLA-DR (Pe-Dazzle 594; BioLegend), and PD-1 (BV605; BD). The intracellular expression of the viral Gag p24 viral protein was detected with a PE-anti-p24 antibody (clone KC57 RD1; Beckman Coulter). A violet viability dye for flow cytometry (LIVE/DEAD Fixable Violet Dead Cell Stain Kit, Invitrogen) was included in all experiments to determine the cell viability. All samples were run on an LSRFortessa fourlaser flow cytometer (Becton Dickinson) and analyzed with FlowJo v10 software (Tree Star).
CD32 expression after in vitro infection of activated CD4
+ T cells PBMCs were isolated from peripheral blood obtained via phlebotomy from HIV-1-negative donors per an active, approved University of Utah IRB protocol (#67637; principal investigator, A. M. Spivak). Total CD4 + T cells were purified via negative magnetic bead selection using a total CD4 + T cell-negative isolation kit (STEMCELL) according to the manufacturer's instructions. CD4 + T cells were cultured in an RPMI 1640-based media supplemented with IL-2 (30 IU/ml) and activated in vitro for 72 hours via exposure to antibodies to CD3 and CD28 conjugated to magnetic beads (Invitrogen). Activated CD4 + T cells subsequently underwent spin infection with an HIV-1 NL4-3 viral strain pseudotyped with green fluorescent protein in place of env (multiplicity of infection of about 1.0 using a titer measured in SupT1 cells) at 1200g for 2 hours at 37°C. CD4 + T cells were stained with the following fluorophore-conjugated antibodies before flow cytometry acquisition: CD3 (PE-Cy7; BioLegend), CD4 (allophycocyanin; Life Technologies), CD32 (PE; Fun-2 clone; BioLegend), CD14 [Brilliant Violet (BV) 421; BioLegend], and HLA-DR (BV 605; BD Biosciences). Flow cytometry was performed at 0, 24, 48, and 72 hours relative to CD4 + T cell isolation, as well as 0, 24, and 48 hours after NL4-3 infection. Flow cytometry acquisition was performed on a BD FACSCanto II instrument, and analysis was performed using FlowJo v10 software.
Ex vivo infection of cervical tissue
Human cervical tissue was obtained from healthy women undergoing hysterectomy for benign indication at University Hospital Germans Trias i Pujol (HUGTP; Badalona, Spain). Informed written consent was obtained from all participants, and the study protocols (IRB protocol number PI-17-159) and questionnaires were approved by the HUGTP Clinical Research Ethics Committee. Tissue was processed within 12 hours after surgery, and 8-mm 3 blocks of mucosal epithelium with the underlying stroma were dissected as previously described (49) . Eight blocks of tissue per condition were placed in RPMI 1640 supplemented with 20% fetal bovine serum (R20) in a 12-well plate and infected with 7200 TCID 50 of the viral stock HIV-1 Bal or medium in control wells. For each experimental condition, duplicates were performed. After 2 hours of incubation at 37°C, tissue blocks were washed three times with 3 ml of phosphate-buffered saline in 6-well plates and placed back in a 12-well plate at eight blocks per well in 1 ml of R20. Infected cervical tissue blocks were cultured for additional 12 days, with a change of medium every 3 days. Tissue digestion with collagenase IV (Invitrogen) and manual dissociation were immediately carried out as previously described (49, 50) . Cells were incubated with Aqua viability dye to distinguish dead cells and with CD45-AF700, CD19-V500, CD3-PerCP, CD4-BV605, CD8-APC, CD14-APC-H7, CD32PE-Cy7, and HLA-DR-BV421 (all from BD Biosciences). After surface staining, cells were intracellularly stained with KC57-PE antibody (Beckman Coulter) to determine p24 expression. All the events were acquired using a BD FACSAria Cell Sorter and analyzed [Flow Cytometry Platform, Germans Trias i Pujol Health Science Research Institute (IGTP)] with FlowJo vX.0.7 software (Tree Star). Gating strategy consisted of a lymphocyte gate based on forward scatter versus side scatter, followed by doublet exclusion, dead and CD19 + cells exclusion, and a CD3 + T cell gate from where the different gates shown were quantified.
RNA in situ hybridization in LNs
Paraffin-embedded LN samples from four viremic and two aviremic ART-treated HIV-infected patients and a healthy donor were obtained from the Anatomical Pathology Department of the Hospital Universitari Vall d'Hebron (Barcelona, Spain). Written informed consent was provided by all of the patients who participated in this study, and the protocols used were approved by the Comité d'Ètica d'Investigació Clínica (IRB number 196-2015) of the Hospital Universitari Vall d'Hebron (Barcelona, Spain). For detection of RNA in paraffin-embedded samples, the ultrasensitive RNA detection assay ViewRNA ISH Tissue 2-Plex Evaluation Kit (eBiosciences) was used. Two high-sensitivity target-specific sets were used: one set of 50 probes spanning the whole Gag-Pol HIV mRNA sequence (bases 1165 to 4402; reference HXB2) and another set of probes designed specifically to hybridize to human CD32a (bases 1046 to 2370; cat. no. VA6-3171678). LN sections of 6 m were mounted on Superfrost Plus microscope slides (Fisher Scientific). The assay was performed as previously described (48) . Briefly, samples were deparaffinized with xylene and dehydrated with decreasing concentrations of ethanol. Section pretreatments were performed by heat-induced epitope retrieval and protease digestion. Next, probe hybridization was carried out by incubation of probes 2 hours at 40°C, and after that, samples were stored overnight in storage buffer (eBiosciences). Finally, signal amplification was performed by sequential incubation with preamplifiers, amplifiers, and substrates. To counterstain slides, 4′,6-diamidino-2-phenylindole staining was performed.
Confocal microscopy and quantification of in situ hybridization LN samples Samples were imaged on an Olympus Spectral Confocal Microscope FV1000 using a 20× and 40× phase objective and sequential mode to separately capture the fluorescence from the different fluorochromes at an image resolution of 800 × 800 pixels. Single HIV-1 RNA-, single CD32a RNA-, or double HIV-1 RNA/CD32a RNApositive cells were determined by visual examination of 23 to 114 B cell follicles per sample. Finally, MFI of HIV-1 RNA-positive cells and CD32a was measured in 10 to 15 B cell follicles using the ImageJ software.
Statistical analyses
Data were analyzed using Prism 6.0 and 7.0 (GraphPad Software). Nonparametric Mann-Whitney U tests, Wilcoxon rank tests, Spearman correlations, and Friedman tests were used, correcting for multiple comparisons with Dunnett's posttest. PCA and hierarchical clustering were performed using R-Studio.
Please refer to the Supplementary Materials for details on antibodies and staining protocols used to phenotype and sort CD32 + CD4 + T cells from human blood and tissue samples, as well as from RM tissues. In addition, the Supplementary Materials contain the details of the qPCR protocols used to measure HIV DNA loads, SIV DNA loads, and cell-associated HIV RNA loads.
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